Summary
RHHBY Chart
U.S.' 'win' in the war has been choking off Iran's oil exports: David Roche
David Roche of Quantum Strategy says oil flows out of the Strait of Hormuz are likely to be far lower than what the U.S. claims. He adds that while Washington's economic pressure on Tehran is growing, it's unlikely to change Iran's strategy of wanting to control the Strait of Hormuz.
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-term dilution risk and enabling multi-indication expansion without sacrificing U.S. economics. Bexobrutideg's Phase 1 data show high response rates in CLL/SLL, with a pivotal Phase 3 trial aiming to demonstrate superiority over pirtobrutinib.
Roche Holding AG Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JEF James E. Francis PARADIGM ASSET MANAGEMENT Co. LLC | 2,000 | $77,534.77 | $110,840 | $33,305.23 | 42.96% |
| GP Gregg Picillo Albert D. Mason Inc | 4,031 | $206,992 | $223,398.02 | $16,406.02 | 7.93% |
| JM John Malone Amundi | 4,601 | $237,007.89 | $264,281.44 | $27,273.55 | 11.51% |
 Michelle Dubey Yousif Capital Management LLC | 52,832 | $2.5M | $2.89M | $383,832.21 | 15.33% |
 Anu Prabhu Altrius Capital Management Inc. | 190,302 | $7.28M | $10.75M | $3.47M | 47.7% |
Roche Holding AG (RHHBY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Roche Holding AG ever had a stock split?
Roche Holding AG Profile
| Pharmaceuticals Industry | Healthcare Sector | Thomas Schinecker CEO | OTCQX Exchange | 771195104 CUSIP |
| CH Country | 103,249 Employees | 13 Mar 2026 Last Dividend | 27 Feb 2014 Last Split | - IPO Date |
Overview
Roche Holding AG is a globally recognized healthcare company that combines its strengths in both pharmaceuticals and diagnostics. With a rich heritage dating back to 1896, the company has established a significant presence across various continents including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. Roche is committed to improving health and well-being by providing innovative solutions and cutting-edge products in multiple therapeutic areas and diagnostics. The company's headquarters are strategically located in Basel, Switzerland, ensuring a pivotal role in the global healthcare sector.
Products and Services
Roche Holding AG offers a diverse portfolio of products and services across a broad spectrum of medical needs and diagnostic requirements. The company’s offerings can be categorized into pharmaceutical products and diagnostic solutions.
- Pharmaceutical Products: Roche is a leader in developing and marketing medicines for a wide range of diseases. Their therapeutic areas include:
- Anemia
- Blood and solid tumors
- Dermatology
- Hemophilia
- Inflammatory and autoimmune diseases
- Neurological disorders
- Ophthalmology
- Respiratory disorders
- Transplantation
- Diagnostic Solutions: In addition to pharmaceuticals, Roche provides a comprehensive range of diagnostic tools. The company's diagnostics division offers in vitro diagnostic tests for a variety of health conditions, including but not limited to:
- Cancer
- Diabetes
- Covid-19
- Hepatitis
- Human Papillomavirus (HPV)
Through its relentless pursuit of innovation and its expansive portfolio, Roche Holding AG is at the forefront of shaping the future of healthcare by addressing some of the most challenging medical needs and advancing global health.
